Venmax Drugs and Pharmaceuticals Limited (BOM:531015)
India · Delayed Price · Currency is INR 13.99
-0.99 (-6.61%)
At close: Sep 22, 2026
BOM:531015 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 92.94 | 80.25 | 8.07 | - | - | - | |
Revenue Growth | 385.68% | 894.04% | 380.89% | - | - | - |
Cost of Revenue | 84.39 | 72.84 | 7.95 | 0.1 | - | - |
Gross Profit | 8.55 | 7.41 | 0.12 | -0.1 | - | - |
Selling, General & Admin | 2.04 | 2.1 | 0.66 | 0.23 | 0.3 | 0.19 |
Other Operating Expenses | 4.51 | 3.87 | -0.65 | 0.73 | 1.55 | 1.08 |
Operating Expenses | 6.6 | 6 | 0.08 | 1.02 | 1.94 | 1.36 |
Operating Income | 1.95 | 1.4 | 0.05 | -1.12 | -1.94 | -1.36 |
Interest & Investment Income | 0 | 1.37 | - | - | - | - |
Other Non Operating Income (Expenses) | 1.61 | 0 | -0 | 1.99 | 4.19 | 19.83 |
EBT Excluding Unusual Items | 3.56 | 2.77 | 0.05 | 0.87 | 2.26 | 18.47 |
Asset Writedown | - | - | -0.19 | - | - | - |
Pretax Income | 3.56 | 2.77 | -0.14 | 0.87 | 2.26 | 18.47 |
Income Tax Expense | 0.29 | 0.29 | -0.04 | 0.22 | 0 | 0 |
Net Income | 3.27 | 2.48 | -0.11 | 0.65 | 2.26 | 18.46 |
Net Income to Common | 3.27 | 2.48 | -0.11 | 0.65 | 2.26 | 18.46 |
Net Income Growth | 1933.54% | - | - | -71.41% | -87.78% | - |
Shares Outstanding (Basic) | 13 | 12 | 5 | 5 | 5 | 5 |
Shares Outstanding (Diluted) | 13 | 12 | 5 | 5 | 5 | 5 |
Shares Change | 156.83% | 121.09% | - | - | - | 0.00% |
EPS (Basic) | 0.24 | 0.21 | -0.02 | 0.12 | 0.43 | 3.52 |
EPS (Diluted) | 0.24 | 0.21 | -0.02 | 0.12 | 0.43 | 3.52 |
EPS Growth | 691.80% | - | - | -72.09% | -87.78% | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -121.5 | -109.96 | -22.9 | 0.02 | -0.03 | 19.05 |
Free Cash Flow Per Share | -9.07 | -9.49 | -4.37 | 0.00 | -0.01 | 3.64 |
Gross Margin | 9.20% | 9.23% | 1.52% | - | - | - |
Operating Margin | 2.10% | 1.75% | 0.58% | - | - | - |
Profit Margin | 3.52% | 3.09% | -1.30% | - | - | - |
Free Cash Flow Margin | -130.73% | -137.03% | -283.69% | - | - | - |
EBITDA | 1.99 | 1.44 | 0.11 | -1.05 | -1.86 | -1.27 |
EBITDA Margin | 2.15% | 1.80% | 1.38% | - | - | - |
D&A For EBITDA | 0.04 | 0.04 | 0.06 | 0.07 | 0.08 | 0.09 |
EBIT | 1.95 | 1.4 | 0.05 | -1.12 | -1.94 | -1.36 |
EBIT Margin | 2.10% | 1.75% | 0.58% | - | - | - |
Effective Tax Rate | 8.03% | 10.37% | - | 25.74% | 0.04% | 0.02% |
Revenue as Reported | 94.55 | 81.85 | 18.61 | 1.99 | 4.19 | 19.83 |
Advertising Expenses | - | 0.07 | 0.07 | - | - | - |